Doctor Blue Bio Tech (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 1075.51%
- Profit Growth 279.59%
- Ebitda 360.99%
- Net Worth 58.53%
- Total Assets -18.39%
About Doctor Blue Bio Tech (India)
Doctor Blue Bio Tech (India) Private Limited (DBBTIPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 April 2011 and has a history of 13 years and nine months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ramulu Gajjela, Hemalatha Gajjela, and Chelamalla Radhika serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233TG2011PTC074031
-
Company No.
074031
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Apr 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Doctor Blue Bio Tech (India)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramulu Gajjela
|
Director | 21-Apr-2011 | Current |
|
Hemalatha Gajjela
|
Director | 28-Jan-2017 | Current |
|
Chelamalla Radhika
|
Director | 02-Nov-2018 | Current |
Financial Performance of Doctor Blue Bio Tech (India).
Doctor Blue Bio Tech (India) Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 1075.51% increase. The company also saw a substantial improvement in profitability, with a 279.59% increase in profit. The company's net worth Soared by an impressive increase of 58.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Doctor Blue Bio Tech (India)?
In 2018, Doctor Blue Bio Tech (India) had a promoter holding of 10.00% and a public holding of 90.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Suprateeka Laboratories Private LimitedRamulu Gajjela and Chelamalla Radhika are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Doctor Blue Bio Tech (India)?
Unlock and access historical data on people associated with Doctor Blue Bio Tech (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Doctor Blue Bio Tech (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Doctor Blue Bio Tech (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
